United Health Products Inc (UEEC)

[DR5]

I think it’s very possible to get closer to “trust’s” numbers. If the human trial shows “superiority” not just “non-inferiority” then HemoStyp becomes much more valuable to the acquirer. And, with patent expiration in 2029, there’s 11 years to milk the profits. The hemostatic market is growing at a quick clip so, our management team will want to get a fair price for all of HemoStyp’s future growth potential. IMO